MedTrace Logo

The Relationship of Hemoglobin A1c and Diabetic Wound Healing

NCT01350102 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-12-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the relationship of hemoglobin A1c in diabetic wound healing. Additionally, a comparison of two wound dressings, AmeriGel® (Amerx Health Care Corp., Clearwater, FL) and Bacitracin, with and without vitamin C supplementation, will be done to evaluate impact on time to wound closure.

Conditions

  • Diabetes, Type 1
  • Diabetes, Type 2
  • Foot Ulcer, Diabetic

Interventions

DRUG

Bacitracin

Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.

DRUG

AmeriGel®

Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.

DIETARY_SUPPLEMENT

Vitamin C

Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve

Sponsors & Collaborators

  • Susan Hassenbein

    lead OTHER

Principal Investigators

  • Nell V. Blake, DPM · Milton S. Hershey Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01350102 on ClinicalTrials.gov